leflunomide has been researched along with Multiple Sclerosis, Relapsing-Remitting in 2 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Multiple Sclerosis, Relapsing-Remitting: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Treatment was well tolerated; numbers of adverse events and serious adverse events were similar in all treatment groups." | 2.72 | A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. ( Bar-Or, A; Confavreux, C; Freedman, MS; Li, D; O'Connor, PW; Paty, DW; Rice, GP; Scheyer, R; Stewart, JA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Millar, JA | 1 |
| O'Connor, PW | 1 |
| Li, D | 1 |
| Freedman, MS | 1 |
| Bar-Or, A | 1 |
| Rice, GP | 1 |
| Confavreux, C | 1 |
| Paty, DW | 1 |
| Stewart, JA | 1 |
| Scheyer, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses[NCT01487096] | Phase 2 | 179 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for leflunomide and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
Topics: Adult; Double-Blind Method; Female; Headache; Humans; Immunologic Factors; Isoxazoles; Leflunomide; | 2006 |
1 other study available for leflunomide and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
The cost of teriflunomide in the treatment of relapsing-remitting multiple sclerosis.
Topics: Australia; Cost-Benefit Analysis; Crotonates; Drug Approval; Drug Costs; Financing, Government; Huma | 2019 |